The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, will tell us how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.
This program has ended. Check our Video Library for a recording.
Date & Time:
Wednesday, January 23, 2019
2:30 - 3:30 pm ET